40164_2017_74_MOESM4_ESM.docx (898.99 kB)
MOESM4 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
journal contribution
posted on 2017-05-18, 05:00 authored by Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max Topp, Nicola Gökbuget, Patrick Baeuerle, Peter Kufer, Andreas Wolf, Matthias KlingerAdditional file 4. Available patient numbers (N) for analysis of distribution profiles of CD8+ and CD4+ T cells and subsets in Fig. 4.